Source: Siyu MedTech; Editor: YiheReprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
Latest news from foreign websites,September 5, 2023DNA sequencing provider Illumina announced the appointment of 48-year-old Jacob Thaysen as the new CEO, who will replace Charles Dadswell.
ApproximatelyTen years ago,Francis deSouzaHe became CEO in 2016, under his leadership, Illumina further expanded its business scope from research laboratories to hospitals and clinics, and launched new instruments that reduce the cost of DNA sequencing into the market.Three months ago, after Francis deSouza left due to a proxy fight, Charles Dadswell has been serving as the interim CEO.According to reports,Jacob ThaysenThe appointment will take effect on September 25, and he will also join the Illumina, Inc. board of directors.。Charles DadswellInFrancis deSouzaAfter resigning, he assumed the position of CEO and is currently still the company's General Counsel.Jacob Thaysen inBefore joining Illumina, he served as the President of Agilent Technologies' Life Sciences and Applied Markets Group.In 2022,This division has become Agilent Technologies' largest division, with an annual revenue of approximately $4 billion.，Total number of customers exceeds 50,000, with an operating profit margin of approximately 30%.Thaysen drove a significant improvement in the operating profit of the department, which is responsible for Agilent Technologies' analytical instrument portfolio, informatics, and cell analysis franchises.From 2014 to 2018,ThaysenServed as the president of Agilent Diagnostics and Genomics Group, during his tenure, the business unit's operating profit nearly doubled.Analyst said: "We are encouraged by Dr. Thaysen's experience in instrumentation (such as mass spectrometry, cell analysis assays) and related consumables, which is essentially the same as Illumina's business model." "The announcement of a permanent CEO should alleviate the pressure on the company's stock, and this positive news will eliminate the distractions caused by the recent frequent departures of senior executives, allowing Illumina to focus on its core objectives."Last month, Illumina appointed a new chief technology officer and announced that its chief medical officer had resigned.。
As the new CEO of Illumina,ThaysenWill need to address a series of imminent challenges, including antitrust regulators in the United States and Europe.Seeking to divest early detection cancer test kit maker Grail。Illumina also faces revenue decline and U.S. securitiesThe Securities and Exchange Commission (SEC) is investigating its 2021 acquisition of Grail.
It is reported that Illumina is still working to complete the acquisition of Grail, a company spun off from Illumina in 2016 that focuses on early cancer detection. In 2020, Illumina announced a $7.1 billion deal to acquire Grail, prior to receiving regulatory approval.Illumina, Inc. has completed the acquisition in advance.But it was later subject to antitrust reviews by the EU and the United States. In April 2023, the U.S. Federal Trade Commission orderedIllumina DivestitureGrail。In July this year, the European Commission fined Illumina approximately $479 million for allegedly violating merger control rules.。An analyst said,Thaysen"Need to further leverage his skills to address the challenge of demand elasticity (for Illumina) and resolve the possibilities regarding Grail and its divestiture." "While we anticipate a more prominent CEO, we believe..."To Jacob ThaysenThe appointment is of constructive significance, as the company needs someone with experience in manufacturing and operations in China.Thaysen"His experience in operations, manufacturing, and China should be beneficial for this position."Jacob ThaysenCurrently 48 years old, heEarned a master's and Ph.D. in physics at the Technical University of Denmark. Has extensive experience in clinical diagnostics (particularly oncology) as well as manufacturing, sales, R&D, and innovation.From 2018 to 2023, he served as Senior Vice President of Agilent Technologies and President of Agilent's Life Sciences and Applied Markets Group (LSAG), which includes Agilent's market-leading businesses in analytical instruments, informatics, and cell analysis. He drove the transformation of analytical laboratories, focusing on integrating innovative and intelligent instruments to build a complete digital lab ecosystem. Additionally, he established Agilent's leadership position in live cell analysis through a series of acquisitions.From 2014 to 2018, Thaysen served as President of Agilent Technologies' Diagnostics and Genomics Group (DGG) and played a key role in the company’s transformation into a life sciences leader. With unique strategic vision and strong commercial leadership, he established a solid growth foundation for Agilent in the diagnostics and clinical sciences business.Before joining Agilent Technologies, Thaysen served as the Vice President of R&D at Dako, a Danish cancer diagnostics company. Prior to Dako, he worked as a management consultant at Copenhagen Consulting (now Bain & Company). Earlier in his career, he was the founder and Chief Technology Officer of Cantion, a Danish research and defense applications development company.ThaysenWill become a member of the Illumina, Inc. board after joining the company.In addition, he will move from Northern California to San Diego.
IlluminaThe company is committed to promoting and inspiring the development of genomics to continuously improve human health. Its focus on innovation has made it a global leader in genomic sequencing and chip technology, providing professional services to customers in research, clinical, and applied markets worldwide.IlluminaThe products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields.
Editor｜Zhao Qing Reviewer｜Yi He Typesetter｜Miya
